
Specialty vaccine company Valneva’s inactivated COVID-19 jab has shown positive results in a Phase I/II trial, with a seroconversion rate …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

